FDA rejects wider use of Theravance's telavancin

11/30/2009 | Reuters

Theravance failed to gain FDA approval to market telavancin, an injectable antibiotic, as a treatment for nosocomial pneumonia. The drug developer said it has the information and analyses needed to address the agency's complete-response letter.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC